In an adult with uncomplicated acute or sub‑acute low back pain, should I use oral corticosteroids (e.g., prednisone) or an intramuscular injection of triamcinolone acetonide, and what are the relative benefits and risks?

Oral Steroids vs Intramuscular Triamcinolone for Low Back Pain

Neither oral corticosteroids nor intramuscular triamcinolone should be routinely used for uncomplicated acute or subacute low back pain, as systemic corticosteroids do not appear to be effective for this indication.

Evidence-Based Recommendation

The highest quality guideline evidence clearly states that systemic corticosteroids do not seem to be effective for low back pain 1. This 2017 American College of Physicians systematic review found that systemic corticosteroids lack efficacy across multiple low back pain presentations.

For Non-Radicular (Axial) Low Back Pain

Both oral and intramuscular corticosteroids should be avoided entirely. The evidence is unequivocal:

• A 2014 randomized controlled trial of oral prednisone (50 mg daily for 5 days) showed no benefit for musculoskeletal low back pain, with more patients in the prednisone group seeking additional medical treatment (40% vs 18%) 2
• A 2006 trial of intramuscular methylprednisolone for non-radicular low back pain found no clinically or statistically significant difference in pain, disability, or healthcare utilization 3
• The 2022 Cochrane review confirmed limited evidence suggesting systemic corticosteroids may be associated with slightly worse short-term pain for non-radicular low back pain 4

For Radicular Low Back Pain (Sciatica)

The evidence is more nuanced but still does not support routine use:

Oral corticosteroids may provide modest short-term functional benefit but do not consistently reduce pain:

• The 2022 Cochrane review (moderate-certainty evidence) found oral/IM corticosteroids probably slightly decrease pain at short-term follow-up (0.56 points on 0-10 scale) and may slightly increase likelihood of functional improvement 4
• However, a 2026 systematic review concluded that oral corticosteroids provide modest functional benefit without consistent pain reduction and are associated with increased short-term adverse events 5
• No difference in need for surgery was demonstrated 4

Intramuscular triamcinolone shows similarly limited benefit:

• A 2008 trial of single-dose IM methylprednisolone (160 mg) for radicular pain was a negative study, though suggested possible benefit in young adults with acute symptoms 6
• The FDA label for IM triamcinolone does not list low back pain as an approved indication 7

Clinical Algorithm

For acute/subacute non-radicular low back pain:

• Do NOT use oral or IM corticosteroids
• These medications provide no benefit and may cause harm

For acute radicular low back pain (sciatica):

• First-line: NSAIDs and conservative management
• If considering corticosteroids after failed conservative therapy:
  • Oral corticosteroids may provide modest functional improvement (not pain relief) at 2-4 weeks
  • Expect minimal clinical benefit (0.5 points on 10-point pain scale)
  • Counsel patients about increased adverse events (hyperglycemia, mood changes, GI upset)
  • IM triamcinolone offers no advantage over oral formulations and is not FDA-approved for this indication
  • Consider epidural steroid injection instead if intervention is warranted (though this is a different route of administration)

Important Caveats

Avoid the deltoid area if IM injection is used, as there is significantly higher incidence of local atrophy; gluteal injection is preferred 7.

Contraindications and warnings for systemic corticosteroids include:

• Active or latent tuberculosis (may reactivate)
• Systemic fungal infections
• Recent myocardial infarction (risk of left ventricular free wall rupture)
• Hepatitis B carriers (risk of reactivation)
• Immunosuppression and infection risk 7

Short-term adverse events are more common with corticosteroids than placebo, including hyperglycemia, mood disturbances, and GI symptoms, though serious adverse events appear rare in short courses 4, 5.

Bottom Line

The evidence does not support routine use of either oral corticosteroids or IM triamcinolone for uncomplicated acute or subacute low back pain. For non-radicular pain, avoid entirely. For radicular pain, the modest functional benefit (without meaningful pain reduction) must be weighed against increased adverse events, and these agents should only be considered after NSAIDs and conservative measures have failed. When systemic corticosteroids are used, oral formulations are preferred over IM triamcinolone, as the latter is not FDA-approved for this indication and offers no demonstrated advantage 1, 4.